logo-loader

Alnylam Pharma's shares leap as it reveals positive results from late-stage trial for a hereditary disease treatment

Last updated: 17:20 20 Sep 2017 BST, First published: 08:19 20 Sep 2017 BST

Drug test
About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) saw its shares leap over 20% in pre-market trading after the drugs firm and its French partner Sanofi SA revealed positive results from a late-stage trial of a treatment for Hereditary ATTR (hATTR) Amyliodosis patients with polyneuropathy.

In a joint statement, the companies said an investigational RNAi therapeutic met its primary and secondary endpoints.

The disease is an inherited one that is progressively debilitating and often fatal and is caused by mutations in the TTR gene - TTR protein is produced in the liver and usually acts as a carrier for vitamin A.

Significant milestone

About 50,000 people worldwide suffer from the disease, which currently has no approved treatment apart from liver transplant.

Elias Zerhouni, president, global R&D at Sanofi said: “This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases."

In pre-market trading in New York,  Alnylam shares were up nearly 22% at US$91.53. 

Later they gained over 35% to stand at US$101.87 each.

Chesnara reports strong 2023 results with improved cash generation and...

Chesnara PLC (LSE:CSN) chief executive Steve Murray discusses the company's full-year results for 2023 with Proactive's Stephen Gunnion, describing them as strong and particularly highlighting £53 million in commercial cash generation and a dividend coverage of around 150%. The company has...

2 hours, 1 minute ago